EDMONTON, April 27 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
financial results for 2004. Several factors contributed to the net loss of
$398,000 in 2004, compared with net income of $442,000 last year. These
included the absence of revenues from the sale of royalties interest units (no
units were offered for sale), the occurrence of, specific, one-time legal and
consulting expenses that were unrelated to regular operations, slightly lower
product sales (including the reduced volume requirements from a major cosmetic
customer) and a shift in product mix resulting in lower margins, higher
general and administrative, royalty, and amortization expenses, a loss on
disposal of property and equipment, and a higher Canadian dollar.
"Overall, 2004 was a positive year for Ceapro," said Dr. Mark Redmond,
Ceapro's President and CEO. "We made significant advances in the area of our
diabetes diagnostic technology, which we have rebranded as CeaProve(TM). We
launched two new products and prototyped three new products for the cosmetics
and personal care industries. We developed seven new concepts for veterinary
therapeutic markets, three of which are proceeding through the development
phase with introductions planned for late 2005. We have also strengthened our
human and capital resources necessary to expand our production capacity to
meet the global demand for our products." Dr. Redmond continued, "The decline
in beta glucan sales was disappointing; however new formulations of beta
glucan, containing major enhancements to reduce shipping and storage costs,
were introduced in late 2004 and we are anticipating increased sales volumes
in 2005."
<<
HIGHLIGHTS
Revenue
$000s 2004 2003 Change
-------------------------------------------------------------------------
Product sales
Active ingredients 1,338 1,680 (20%)
Veterinary therapeutic products 619 538 15%
-------------------------------------------------------------------------
1,957 2,218 (12%)
Royalties, licenses, and product development 463 206 125%
-------------------------------------------------------------------------
Total revenues 2,420 2,424 -
-------------------------------------------------------------------------
Total revenues, which include product sales and royalties, licenses, and
product development fees, were comparable to last year, at $2.4 million. The
overall volume of sales increased slightly in 2004 but the rising Canadian
dollar negatively impacted recorded revenues.
General and Administrative
$000s 2004 2003 Change
-------------------------------------------------------------------------
Salaries and benefits 265 267
Consulting 56 55
Travel, accommodation, meals and entertainment 30 31
Computer systems and support 24 2
Insurance 99 80
Rent 49 40
Board of Directors compensation 65 51
Investor relations 97 78
Legal 36 33
Other 112 120
-------------------------------------------------------------------------
Total general and administrative expenses 833 757 10%
-------------------------------------------------------------------------
General and administrative expenses (G&A) rose 10% due to several
factors. Additional computer systems support costs were incurred for planning
and implementation for Ceapro's redeveloped website and upgrading internal
computer network systems required to support our business. Higher insurance
costs resulted from an increase in coverage to accommodate growth in our
business, provide adequate coverage, and an overall premium rate increase
versus last year. Increased volume and costs associated with required
information reporting and shareholder mailings, and developmental activities
undertaken for investor relations communications strategy and materials
increased investor relations and stock listing fees. The Board of Directors'
compensation increased as a result of changing to a fee-based compensation
structure from a stock-based compensation structure. During the year all
Directors exercised stock options in amounts sufficient to fund the fees
payable to them for the year. Ceapro's rent also increased as a direct result
of the relocation of the offices to new space within the Research Transition
Facility located on the University of Alberta Campus.
Sales and Marketing
$000s 2004 2003 Change
-------------------------------------------------------------------------
Salaries and benefits 82 133
Consulting 33 16
Travel, accommodation, meals and entertainment 9 80
Other 7 2
-------------------------------------------------------------------------
Total sales and marketing expenses 131 231 (43%)
-------------------------------------------------------------------------
Sales and marketing expenses declined 43% largely due to a reduction of
time spent on marketing activities by senior management and scientific
personnel, lower travel and related. Throughout the year, senior management
and scientific personnel were required to spend significant time renewing,
refreshing and reformulating existing products and were not as available to
support the sales and marketing efforts. Consulting expenses rose as
additional advisory services were required to support Ceapro's international
customers on existing and new product sales, and new distribution and
licensing agreements.
Royalties
$000s 2004 2003 Change
-------------------------------------------------------------------------
Royalty interest units 203 121
AVAC royalty 74 58
-------------------------------------------------------------------------
Total royalties expenses 277 179 55%
-------------------------------------------------------------------------
Royalties expense increased 55% year-over-year. This increase is related
to the timing of royalties earned by investors who participated in the Royalty
Interest and Royalty Income Unit offerings completed throughout 2003, and the
higher royalties earned by AVAC Ltd. on eligible product sales due to a shift
in product sales mix.
Quarterly Information
The following selected financial information is derived from Ceapro's
unaudited quarterly financial statements for each of the last eight quarters,
all of which cover periods of three months.
$000s
except
per 2004 2003
share ------------------------------- -------------------------------
data Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
-------------------------------------------------------------------------
Total
revenues 469 414 975 561 590 485 865 484
Net income
(loss) (78) (361) (71) 113 (139) 331 220 30
Basic
income
(loss)
per
share (0.002) (0.010) (0.002) 0.003 (0.004) 0.008 0.007 0.001
Diluted
income
(loss)
per
share (0.002) (0.010) (0.002) 0.003 (0.004) 0.007 0.007 0.001
Ceapro's quarterly results fluctuate primarily due to variations in the
timing and proceeds of various public and private income offerings, product
sales, and royalty and license fees. In 2003 and 2004, the results are
negatively impacted by foreign exchange due to the significant strengthening
of the Canadian dollar.
Outlook
On March 31, 2005, we completed a private placement share offering of
682,666 Units, for aggregate gross proceeds of $204,800. We continue to pursue
additional financings to fund on-going working capital requirements and to
secure the financial resources required to support the expected increases in
the volume of sales of existing products, the introduction of new products to
existing and new markets, and the development of new technology. Our operating
plans will continue to be implemented in a measured and responsible manner and
we caution that additional investments required to continue to expand the
business and product lines may affect the pace of growth.
While we incurred a loss for the year, we remain positive in our business
outlook. A number of recent initiatives should result in increased sales in
2005 and beyond. Our order book is beginning to fill for the second quarter,
evidence that active ingredient sales are beginning to recover as the
reformulated beta-glucan product is introduced to customers and incorporated
into new or existing product formulations. We have made strides in the
commercialization of CeaProve(TM), our diabetes diagnostic product,
identifying new applications in the areas of diabetes monitoring and drug
dosage determination. The signing of new distribution agreements for
veterinary therapeutic products in Asia and Canada, the development of new
veterinary therapeutic products and their addition to the Japan distribution
agreement all pave the way for increased sales throughout 2005.
Ceapro advises that its audited financial statements for the year ended
December 31, 2004, and accompanying management's discussion and analysis, has
been filed with securities regulators and is available on www.sedar.com. The
Company's annual report will be mailed to shareholders on or about May 2,
2005. The annual meeting of shareholders will take place in Edmonton, on
June 1, 2005.
About Ceapro Inc.
Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.30.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.
This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the
forward-looking statements contained herein are reasonable, it can give no
assurance that the Company's expectations are correct. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement.
Consolidated Balance Sheets
Unaudited
December 31 December 31
2004 2003
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
Cash $ 96,266 $ 248,443
Accounts receivable 375,160 514,154
Inventories 345,424 115,556
Prepaid expenses and deposits 66,473 29,971
Deferred charges 50,000 -
-------------------------------------------------------------------------
933,323 908,124
RESTRICTED CASH FOR THE PURCHASE OF PROPERTY
AND EQUIPMENT 64,430 -
PROPERTY AND EQUIPMENT 720,067 347,188
-------------------------------------------------------------------------
$ 1,717,820 $ 1,255,312
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES
CURRENT LIABILITIES
Accounts payable and accrued liabilities $ 713,201 $ 433,594
Deferred revenue 80,000 -
Callable debt 122,296 159,683
Current portion of convertible debentures 17,510 9,436
Current portion of long-term debt 28,234 40,000
Current portion of royalties payable 104,498 102,029
-------------------------------------------------------------------------
1,065,739 744,742
CONVERTIBLE DEBENTURES - 17,510
LONG-TERM DEBT 471,766 4,832
ROYALTIES PAYABLE 66,249 105,998
-------------------------------------------------------------------------
1,603,754 873,082
-------------------------------------------------------------------------
SHAREHOLDERS' EQUITY
SHARE CAPITAL 1,995,443 1,855,823
CONTRIBUTED SURPLUS 121,997 132,044
DEFICIT (2,003,374) (1,605,637)
-------------------------------------------------------------------------
114,066 382,230
-------------------------------------------------------------------------
$ 1,717,820 $ 1,255,312
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Consolidated Statements of Income (Loss) and Deficit
Unaudited
Twelve Months Ended Quarters Ended
December 31 December 31
2004 2003 2004 2003
-------------------------------------------------------------------------
Revenue
Sales $ 1,956,961 $ 2,218,262 $ 299,206 $ 577,363
Cost of goods sold 1,022,831 928,115 186,055 192,667
-------------------------------------------------------------------------
Gross margin 934,130 1,290,147 113,151 384,696
Royalties, licenses,
and product
development fees 462,758 206,098 170,000 12,960
-------------------------------------------------------------------------
1,396,888 1,496,245 283,151 397,656
-------------------------------------------------------------------------
Expenses
General and
administration 833,346 756,716 199,665 191,131
Sales and marketing 130,578 230,701 34,787 72,515
Royalties 277,149 179,475 51,499 60,761
Interest on
convertible
debentures and
other 7,383 32,149 1,608 1,990
Interest on
long-term debt 21,120 15,624 10,537 5,028
Amortization 91,962 59,960 29,481 21,721
-------------------------------------------------------------------------
1,361,538 1,274,625 327,577 353,146
-------------------------------------------------------------------------
Income (loss) from
operations 35,350 221,620 (44,426) 44,510
-------------------------------------------------------------------------
Other income (expenses)
Other income
(expenses) (118,211) 574,162 20,909 (56,630)
Research and product
development (302,487) (353,744) (54,322) (126,304)
Loss on disposal of
property and
equipment (12,389) - - -
-------------------------------------------------------------------------
(433,087) 220,418 (33,413) (182,934)
-------------------------------------------------------------------------
Income (loss) before
income taxes (397,737) 442,038 (77,839) (138,424)
Income taxes
Current 654,483 275,437 - -
Reduction as a
result of applying
non-capital losses
carried forward
against the
current period's
taxable income (654,483) (275,437) - -
-------------------------------------------------------------------------
NET INCOME (LOSS) FOR
THE PERIOD (397,737) 442,038 (77,839) (138,424)
Deficit at beginning
of period (1,605,637) (2,047,675) (1,925,535) (1,467,213)
-------------------------------------------------------------------------
DEFICIT AT END OF
PERIOD $(2,003,374) $(1,605,637) $(2,003,374) $(1,605,637)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net income (loss) per
share :
Basic $ (0.011) $ 0.014 $ (0.002) $ (0.004)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Diluted $ (0.011) $ 0.013 $ (0.002) $ (0.004)
-------------------------------------------------------------------------
Consolidated Statements of Cash Flows
Unaudited
Twelve Months Ended Quarters Ended
December 31 December 31
2004 2003 2004 2003
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net income (loss)
for the period $ (397,737) $ 442,038 $ (77,839) $ (138,424)
Items not affecting
cash
Amortization 91,962 59,960 29,481 21,721
Loss on disposal
of property and
equipment 12,389 - - -
Conversion of
debentures,
loans, and
interest to
royalty
interest - (304,123) - -
Stock-based
compensation 19,006 89,872 572 9,587
-------------------------------------------------------------------------
(274,380) 287,747 (47,786) (107,116)
Changes in
non-cash working
capital items
Accounts
receivable 138,994 (239,286) (243,171) (45,775)
Inventories (229,868) (58,739) 18,359 (61,285)
Prepaid expenses
and deposits (36,502) (15,212) (28,958) (7,498)
Deferred charges (50,000) - (50,000) -
Accounts payable
and accrued
liabilities 279,607 96,061 154,681 40,984
Deferred revenue 80,000 - 80,000 -
-------------------------------------------------------------------------
(92,149) 70,571 (116,875) (180,690)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Purchase of
property and
equipment (477,230) (133,637) (149,950) (8,602)
Restricted cash
for purchase of
property and
equipment (64,430) - (64,430) -
-------------------------------------------------------------------------
(541,660) (133,637) (214,380) (8,602)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Increase
(decrease) in
long-term debt 417,781 (112,019) 264,106 (23,994)
Increase in share
capital 111,131 354,755 67,544 235,895
Decrease in
convertible
debentures (10,000) (15,000) - -
Increase
(decrease) in
royalties
payable (37,280) 58,381 (7,734) 11,732
-------------------------------------------------------------------------
481,632 286,117 323,916 223,633
-------------------------------------------------------------------------
Increase (decrease)
in cash (152,177) 223,051 (7,339) 34,341
Cash at beginning of
period 248,443 25,392 103,605 214,102
-------------------------------------------------------------------------
CASH AT END OF
PERIOD $ 96,266 $ 248,443 $ 96,266 $ 248,443
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Supplementary
information:
Interest paid $ 26,300 $ 55,018 $ 12,067 $ 1,686
Royalties paid $ 312,502 $ 79,271 $ 59,233 $ 36,080
>>
%SEDAR: 00010110E
Ceapro announces 2004 financial results
Earlier from Ceapro
- Ceapro receives further investment from AVAC Ltd.
- Ceapro announces new Controller
- Ceapro rebrands patented diabetes technology as CeaProve(TM)
Later from Ceapro
- Ceapro to present at BioFinance conference
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
- Ceapro announces officer appointment
- Ceapro Announces Granting of Stock Options
- Ceapro announces 2005 second quarter financial results
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro